Pharvaris to Present in Upcoming March Investor Conferences

Rhea-AI Summary

ZUG, Switzerland, March 02, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS) announced participation in two investor conferences in March. The first event is the BioCapital Europe 2023, taking place in Amsterdam on March 9, 2023, at 11:00 a.m. CET. The second is the Oppenheimer 33rd Annual Healthcare Conference, a virtual presentation scheduled for March 13, 2023, at 2:00 p.m. CET. A live audio webcast of the latter will be accessible on Pharvaris' website, with a replay available for 30 days. Pharvaris specializes in developing oral bradykinin-B2-receptor antagonists for treating hereditary angioedema (HAE), aiming to provide effective treatment options.

ZUG, Switzerland, March 02, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced that management will participate in two upcoming investor conferences in March:

BioCapital Europe 2023
Format: Live In-Person Presentation
Date/Time: Thursday, March 9, 2023, at 11:00 a.m. CET (5:00 a.m. EST)
Location: Amsterdam, Netherlands

Oppenheimer 33rd Annual Healthcare Conference
Format: Webcasted Virtual Presentation
Date/Time: Monday, March 13, 2023, at 2:00 p.m. CET (8:00 a.m. EST)
Location: Virtual

A live audio webcast of the Oppenheimer 33rd Annual Healthcare Conference presentation will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations. A replay will be available on Pharvaris’ website for 30 days following the presentation.

About Pharvaris
Pharvaris is a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in HAE. By directly targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE safe, effective, and convenient alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit https://pharvaris.com/.

Contact
Maryann Cimino
Director of Corporate Relations
maryann.cimino@pharvaris.com 
+1-617-710-7305

FAQ

What conferences is Pharvaris participating in March 2023?

Pharvaris is participating in BioCapital Europe 2023 on March 9, 2023, and the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023.

What is the date and time for the BioCapital Europe 2023 event?

The BioCapital Europe 2023 event will take place on March 9, 2023, at 11:00 a.m. CET.

When will the Oppenheimer Healthcare Conference presentation be held?

The Oppenheimer 33rd Annual Healthcare Conference presentation is scheduled for March 13, 2023, at 2:00 p.m. CET.

Where can I watch the Pharvaris presentation from the Oppenheimer conference?

The Pharvaris presentation will be available via live audio webcast on their website, with a replay accessible for 30 days afterward.

What is the focus of Pharvaris as a company?

Pharvaris focuses on developing novel oral bradykinin-B2-receptor antagonists aimed at treating and preventing hereditary angioedema (HAE) attacks.